Oncotarget

Research Papers:

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool

Philipp O. Tsvetkov, Emeline Tabouret, Andrei Y. Roman, Sylvie Romain, Céline Bequet, Olga Ishimbaeva, Stéphane Honoré, Dominique Figarella-Branger, Olivier Chinot and François Devred _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:9391-9399. https://doi.org/10.18632/oncotarget.24317

Metrics: PDF 1398 views  |   HTML 2394 views  |   ?  


Abstract

Philipp O. Tsvetkov1, Emeline Tabouret1,2, Andrei Y. Roman1,5, Sylvie Romain3, Céline Bequet2, Olga Ishimbaeva1, Stéphane Honoré1, Dominique Figarella-Branger4, Olivier Chinot1,2 and François Devred1

1Aix-Marseille Université, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie de Marseille, 13385 Marseille, France

2AP-HM, Hôpital de la Timone, Service de Neuro-Oncologie, 13005 Marseille, France

3AP-HM, Faculté de Médecine Nord, Service de Transfert d’Oncologie Biologique, 13015 Marseille, France

4AP-HM, Hôpital de la Timone, Service d'Anatomopathologie, 13005 Marseille, France

5Institute of Physiologically Active Compounds, RAS, 142432 Chernogolovka, Russian Federation

Correspondence to:

François Devred, email: [email protected]

Keywords: glioblastoma; differential scanning calorimetry; disease monitoring; plasma; calorimetric signature

Received: August 20, 2017    Accepted: January 09, 2018    Published: January 25, 2018

ABSTRACT

Glioblastoma is the most frequent and aggressive primary brain tumor in adults. Recently, a growing number of studies have shown that denaturation profile of plasma samples obtained by differential scanning calorimetry (DSC) can represent a signature of a disease. In this study, we analyzed for the first time the DSC denaturation profiles of the plasma from patients with recurrent glioblastoma (n=17). Comparison to the one of healthy individuals (n=10) and to already described profiles in others cancer showed clear differences suggesting that this DSC profile may constitute a signature of glioblastoma. Parameters extracted from these profiles were used for cluster analysis which revealed the existence of glioblastoma profile subgroups which correlated with prognostic factors. Moreover, we showed that the presence of circulating bevacizumab and carmustine did not alter this calorimetric signature of the disease, indicating that an evolution of the profile could be followed without being masked by ongoing systemic treatment. Thus, our results constitute a very promising proof of principle that a specific calorimetric profile could be detected in the plasma of glioblastoma patients. Moreover, we believe that our findings point to a potential easy-to-use non-invasive monitoring tool for glioblastoma patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24317